Please Wait
Applying Filters...
menu
    • menu
    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Cefoperazone Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 126Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Sulperazon

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Sulperazon

    Cefoperazone

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2019 Revenue in Millions : 684

    2018 Revenue in Millions : 613

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Sulperazon

    Cefoperazone

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2020 Revenue in Millions : 618

    2019 Revenue in Millions : 684

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Sulperazon

    Cefoperazone

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone

    Main Therapeutic Indication : Nephrology

    Currency : USD

    2021 Revenue in Millions : 683

    2020 Revenue in Millions : 618

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Sulperazon

    Cefoperazone

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2022 Revenue in Millions : 786

    2021 Revenue in Millions : 683

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Sulperazon

    Cefoperazone

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2023 Revenue in Millions : 757

    2022 Revenue in Millions : 786

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Sulperazon

    Cefoperazone/Sulbactam

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone/Sulbactam

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2024 Revenue in Millions : 637

    2023 Revenue in Millions : 757

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Sulperazon

    Cefoperazone and Sulbactam

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone and Sulbactam

    Main Therapeutic Indication : Urology

    Currency : USD

    2014 Revenue in Millions : 14.90%

    2013 Revenue in Millions :

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Sulperazon

    Cefoperazone and Sulbactam

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone and Sulbactam

    Main Therapeutic Indication : Urology

    Currency : USD

    2015 Revenue in Millions : 354

    2014 Revenue in Millions : 339

    Growth (%) : -4%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Sulperazon

    Cefoperazone And Sulbactam

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer

    Cefoperazone And Sulbactam

    Main Therapeutic Indication : Urology

    Currency : USD

    2016 Revenue in Millions : 396

    2015 Revenue in Millions : 339

    Growth (%) : 17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Sulperazon

    Cefoperazone and Sulbactam

    arrow
    IFT FIRST
    Not Confirmed

    Brand Name : Sulperazon

    U.S.A
    arrow
    IFT FIRST
    Not Confirmed

    Pfizer Inc.

    Cefoperazone and Sulbactam

    Main Therapeutic Indication : Urology

    Currency : USD

    2017 Revenue in Millions : 471

    2016 Revenue in Millions : 396

    Growth (%) : 19

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF